UCeed Child Health and Wellness Fund
Canada's first early-stage investment fund for child and maternal health, creating positive health impacts for children and families.
UCeed Child Health is funded by the generosity of our community through the Alberta Children’s Hospital Foundation and their mission to inspire our community to invest in excellence in child health, research and family centred care.
Investment and fund eligibility
Investment
$50,000 up to $300,000
Criteria
- Applicant must have an established relationship with the University of Calgary as a current, past or visiting faculty member, a student, or has licensed or assigned intellectual property developed at the University of Calgary.
- For-profit enterprise
- Technology Readiness Level (TRL): Stage 1-9
- Must be incorporated prior to receipt of funds
- Minimum one (1) full-time employee within six (6) months of UCeed investment
To be considered for investment
UCeed funds meet with prospective companies on an ongoing basis. Please fill out the short application (5 minutes) which will also require you to upload your pitch deck.
Our Investments
Learn more about our investments and how they are making an impact.
Investment Advisory Group - Child Health and Wellness Fund
Mike Begin
Meg Bregazzi
Chen Fong
Derrick Hunter
Zain Kassam
James Lochrie
Alice Reimer
Clinical Advisory Board
The marketplace success of novel therapeutics, diagnostics, medical devices, and other healthcare products often depends on nuanced factors that require frontline clinician feedback to assess. The Clinical Advisory Board (CAB) is a group of physician volunteers who leverage their networks to connect UCeed Health staff to frontline clinicians who provide feedback on the clinical utility and feasibility of healthcare products and services in development by prospective investee companies. We are deeply grateful for their valuable assistance.
Child Health Fund Portfolios
AazeinTx
AazeinTx is commercializing a novel, fast-acting, orally delivered compound for the treatment of acute and chronic asthma.
All Skin
All Skin is improving access to dermatology-backed skincare information through its mobile app and B2B services, making it easier for people with skin conditions, skincare enthusiasts and general consumers to find the right products and routines suited to their own skin.
Child Health Imprints
Child Health Imprints is giving preterm babies a better chance at life with data-monitoring technology that supports clinicians.
Fluid Biomed
Fluid Biomed is revolutionizing the approach to vascular disease by creating the first bioabsorbable brain stent to treat aneurysms.
Medhesion
Medhesion is developing a solution for post-surgery abdominal adhesions, a potentially life-threatening complication that affects hundreds of thousands of patients each year.
Nimble Science
Nimble Science is developing an ingestible medical device capsule that samples small intestine contents for microbiome diagnostic applications obviating the need for invasive endoscopy procedures.
Noa Therapeutics
Noa Therapeutics is developing multimodal therapeutics to address the complexity of immune diseases, innovation that will help break the cycle of trial-and-error treatment failures.
Probius
Probius, a front-runner in the techbio industry, is developing software that will improve predictive insight into disease and increase the pace of biomedical research.
Sequence2Script
Sequence2Script is a SaaS tool to help healthcare providers and clinical laboratories translate pharmacogenetic test results into clinically useful recommendations.
SMöLTAP
SMöLTAP is a revolutionary infant spinal tap positioning solution that can improve first attempt success rates in spinal tap procedures.
Trexo Robotics
Trexo Robotics has developed a sophisticated wearable robotic device to provide physiotherapy for children with walking impairments. The device monitors a child’s ability to move their legs with artificial intelligence algorithms and provides a level of assistance that maximizes therapeutic benefit.
Xploro Inc.
Xploro Inc. uses artificial intelligence to ease procedural anxiety and reduce stress in children with cancer.
Zymedyne
Zymedyne is developing therapeutics for the treatment of chronic pain that targets a recently discovered biological process that is abnormally activated in chronic pain conditions, offering an alternative to opioids.